

QIBA Dynamic Contrast Enhanced (DCE) MRI Biomarker Committee (BC) Call

Monday, March 4, 2019 at 11 AM (CT)

Call Summary

Participants

Caroline Chung, MD (Co-Chair)

Hendrik Laue, PhD (Co-Chair)

Michael Boss, PhD

Martin Büchert, PhD

Catherine Coolens, PhD

Dena Flamini, RT

Jacob Fluckiger, PhD

Wei Huang, PhD

Harrison Kim, PhD, MBA

Cristina Lavini, PhD

Nancy Obuchowski, PhD

Mark Shiroishi, MD

Kyunghyun Sung, PhD

RSNA

Joe Koudelik

Susan Stanfa

DCE Profile Update (Dr. Laue)

- DCE BC members were encouraged to review and comment on the updated Profile at:
<https://docs.google.com/document/d/1ytAuSsRtL2mgAIY1wq6PkVGleWvWSTdxOHGdgUu1mrA/edit?usp=sharing>
- B1 mapping/-correction issue
 - Next steps are:
 - Decide how to include B1 in the DCE Profile
 - Provide B1 mapping data from Dr. Nayak's groundwork project
 - Request software description from vendors
 - Inquiries have been submitted to vendor representatives to find out whether they plan to utilize B1 mapping correction within their analysis software; Dr. Sung to remind Dr. Nayak that an update is needed
 - Discussion on this topic to resume during the March 18 call
- Section 3: Dr. Laue provided an overview of Profile edits made since the Feb 18 call
 - Specification tables vs. general discussion content reviewed
- Section 3.5: Periodic QA
 - High-level T1/R1 Phantom scanning precision text to remain in 3.5.1 discussion section; this will describe what users need to do to be QA conformant with the Profile
 - Specifics regarding T1 or R1 reference values or ranges to be moved to Section 4.1: Assessment Procedure: R1/T1 Mapping accuracy
 - Dr. Laue to make changes offline following the meeting
- Section 3.5.2 Periodic QA Specification Table
 - Comment that Profile writers should be selective about what information appears in the main body of Profile
 - Recommendation to minimize conformance items on the checklist
- Section 3.6: Protocol Design
 - Specification text critical to conformance to be moved to section 3.5
 - Dr. Lavini will either add comment to the Profile directly (or email text to Dr. Laue) regarding phantom usage (e.g., number of scans/slices recommended) in section 3.6.1

- Section 3.7: Subject Selection
 - Nuances regarding contrast enhancement, double-dosing and acceptable dose ranges discussed
 - Current text indicates: “If a patient needs adjustment in gadolinium dose and bolus injection rate beyond the recommended conditions listed in this Profile, the Claims of the Profile may not apply”
 - There was discussion regarding placing a limit on gadolinium dose
- In efforts to finalize the Profile, DCE BC members were asked to review Section 4: Assessment Procedures and make comments on the Profile Google Doc or bring feedback to the March 18 call

Next DCE BC Call: Monday, March 18, 2019 at 11 AM CT

RSNA Staff attempt to identify and capture all committee members participating on WebEx calls. However, **if multiple callers join simultaneously or call in without logging on to the WebEx, identification is not possible.** Call participants are welcome to contact RSNA staff at QIBA@RSNA.org if their attendance is not reflected on the call summaries.